BMRN
HOLD / NEUTRALMeanRevComposite
54.20
Technical
89.30
Fundamental
42.50
Rank
—
Price
69.55
Hurst
0.19
As of
Aug 12, 2026
Daily
BioMarin Pharmaceutical Inc.
HealthcareBiotechnologyBioMarin Pharmaceutical develops and sells medications to treat rare genetic and metabolic disorders worldwide. The company's marketed therapies address conditions including mucopolysaccharidosis variants, achondroplasia, phenylketonuria, and Batten disease, with a pipeline that includes experimental treatments for growth disorders and muscular dystrophy. The biotechnology firm distributes its products through specialty pharmacies, hospitals, and wholesalers globally.
Market cap
$11.3B
P/E (trailing)
158.14
P/E (forward)
9.12
PEG ratio
0.34
Dividend yield
0.00%
Beta
0.22
52w range
49.26 – 70.98
Return on equity
+1.18%
Profit margin
+2.14%
Revenue growth
+19.90%
Earnings growth
-81.30%
Price history
1Y: 58.51 (+9.2%) · range 49.67–70.24
Cycle position
38/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 43 · WEAK SETUP · exit proximity 0
Conviction
30/ 100 · maturity 0%
Buildup.335
EMA entry setup.4243
Fundamentals.2543
Volume profile
POC
55.56
Price vs POC
+5.3%
Overhead supply
48%
Runway
+0.9%
Value area 51.87–63.16 · 48% of 120d volume overhead · moderate overhead
Get an AI analyst's read on this ticker.Open the AI analyst
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -6.73% | -1.30% | mature |
| 40d | -21.85% | -1.30% | mature |